Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients with recurrent or refractory solid tumors or sarcomas.
Detailed description
PRIMARY OBJECTIVES: I. Determine the tolerability, and define and describe the toxicities of nivolumab administered as a single agent in children with relapsed or refractory solid tumors at the adult recommended dose of 3 mg/kg. II. Determine if systemic nivolumab exposure in children is similar to the systemic exposure in adults following a 3 mg/kg dose. III. Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and define and describe the toxicities of nivolumab plus ipilimumab administered to children with relapsed or refractory solid tumors. IV. Assess antitumor effects of nivolumab across selected childhood solid tumors in seven expansion cohorts (Parts B1-B6, B8); neuroblastoma (2 cohorts: measurable disease, metaiodobenzylguanidine \[MIBG\] positive only non-measurable disease), osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma. V. Assess antitumor effects of nivolumab in combination with ipilimumab across selected childhood solid tumors in two dose combinations (Part D and Part E). VI. Characterize the pharmacokinetics of nivolumab alone and in combination with ipilimumab, including area under the curve (AUC), concentration maximum (Cmax), concentration minimum (Cmin), using intensive sampling. VII. Assess immunogenicity of nivolumab alone and in combination with ipilimumab by measuring anti-drug antibody (ADA) levels. SECONDARY OBJECTIVES: I. Conduct exploratory studies of the phenotypic and functional effects of nivolumab (alone and in combination with ipilimumab), as well as changes in antibodies to previously vaccinated viruses, in serum samples. II. Explore whether correlations exist between PD-L1 expression on tumor and antitumor effects of nivolumab (alone and in combination with ipilimumab) in pediatric solid tumors and to conduct exploratory studies of potential tumor associated biomarkers of response in tumor tissue (at least five out of the following markers: NRAS, BRAF, MEK, KIT, PDGF, TP53, RB1 and BRCA1, Akt phosphorylation, IL-17 or PD-L1). III. Explore presence of tumor infiltrating lymphocytes and their association with antitumor effects of nivolumab (alone and in combination with ipilimumab). IV. Conduct exploratory studies of the effect of nivolumab (alone or in combination with ipilimumab) on cytokine levels in serum samples. V. For Part E, determine tumor mutational burden of diagnostic specimens using FoundationOneCDx testing to explore immune- related gene expression or mutation and its association with antitumor response to nivolumab in combination with ipilimumab. OUTLINE: This is a phase I, dose-escalation study of nivolumab followed by a phase II study. PART A (COMPLETED): Patients with recurrent or refractory solid tumors receive nivolumab intravenously (IV) over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. PART B (COMPLETED): Patients with neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, non-Hodgkin lymphoma, or melanoma receive nivolumab as in Part A. PART C (COMPLETED): INDUCTION: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive nivolumab IV as in Part A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. PART D (COMPLETED): INDUCTION: Patients with neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, non-Hodgkin lymphoma, or melanoma receive nivolumab IV and ipilimumab IV as in Part C. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. PART E: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at approximately 100 days, every 6 months for up to 24 months, and then annually for up to 60 months.
Interventions
Given IV
Correlative studies
Given IV
Correlative studies
Sponsors
Study design
Eligibility
Inclusion criteria
* Parts A & C: patients must be \>= 12 months and \< 18 years of age at the time of study enrollment * Parts B1-B6, B8, D1-D6, E3, E4: patients must be \>= 12 months and =\< 30 years of age at the time of study enrollment * Part B7: patients must be \>= 12 months and \< 18 years of age at the time of study enrollment * Patients must have had histologic verification of malignancy at original diagnosis or relapse * Parts A & C: patients with recurrent or refractory solid tumors, without central nervous system (CNS) tumors or known CNS metastases, are eligible; note: CNS imaging for patients without a known history of CNS disease is only required if clinically indicated * Part B1: patients with relapsed or refractory neuroblastoma * Part B2: patients with relapsed or refractory osteosarcoma * Part B3: patients with relapsed or refractory rhabdomyosarcoma * Part B4: patients with relapsed or refractory Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) * Part B5: patients with relapsed or refractory Hodgkin lymphoma * Part B6: patients with relapsed or refractory non-Hodgkin lymphoma * Part B7: patients with unresectable melanoma or metastatic melanoma or relapsed melanoma or refractory melanoma * Part B8: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without Response Evaluation Criteria in Solid Tumors \[RECIST\] measurable lesion) * Once the dose-escalation portion of Part A is completed, cohorts that are open concurrently for eligible patients (including Parts B and C and potential pharmacokinetic \[PK\] expansion cohorts) may be selected at the treating physician's discretion pending slot availability; in the event a disease group cohort in Part B is completed after the initial stage of Simon's optimal two-stage design, for selected disease cohorts, a corresponding cohort in the same disease group for select disease types will be open in Part D: * Part D1: Patients with relapsed or refractory neuroblastoma * Part D2: Patients with relapsed or refractory osteosarcoma * Part D3: Patients with relapsed or refractory rhabdomyosarcoma * Part D4: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET * Part D5: Patients with relapsed or refractory non-Hodgkin lymphoma * Part D6: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion) * Part E3: Patients with relapsed or refractory rhabdomyosarcoma * Part E4: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET * Parts A & C: patients must have either measurable or evaluable disease * Parts B, D & E: patients must have measurable disease for Parts B1-B6, D1-D5, E3 and E4; melanoma patients in Part B7 must have either measurable or evaluable disease; neuroblastoma patients in Parts B8 and D6 must be evaluable for MIBG response without evidence of RECIST measurable lesions * Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 60 for patients =\< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately * Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive * At least 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea) * Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair * Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count \[ANC\] counts): At least 7 days after the last dose of agent * Interleukins, interferons and cytokines (other than hematopoietic growth factors): \>= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors) * Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1 * External beam radiation therapy (XRT)/external beam irradiation including protons: \>= 14 days after local XRT; \>= 150 days after total body irradiation (TBI), craniospinal XRT or if radiation to \>= 50% of the pelvis; \>= 42 days if other substantial bone marrow (BM) radiation. * Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): \>= 42 days must have elapsed since systemically administered radiopharmaceutical therapy * Cellular therapy: \>= 42 days must have elapsed since the completion of any type of cellular therapy (e.g. modified T cells, natural killer \[NK\] cells, dendritic cells, etc.) * Patients must not have received prior exposure to nivolumab; for patients enrolled in Parts C, D, and E patients must not have received prior nivolumab or ipilimumab * For patients with solid tumors without known bone marrow involvement: * Peripheral absolute neutrophil count (ANC) \>= 750/mm\^3 * Platelet count \>= 75,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) * Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor must be evaluable for hematologic toxicity, for Parts A and C; if dose-limiting hematologic toxicity is observed on either Part A or C, all subsequent patients enrolled must be evaluable for hematologic toxicity on that Part * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * Age 1 to \< 2 years: maximum serum creatinine (mg/dL) 0.6 for males and females * Age 2 to \< 6 years: 0.8 for males and females * Age 6 to \< 10 years: 1 for males and females * Age 10 to \< 13 years: 1.2 for males and females * Age 13 to \< 16 years: 1.5 for males and 1.4 for females * Age \>= 16 years: 1.7 for males and 1.4 for females * Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L * No evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry \> 92% while breathing room air * Serum lipase =\< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored * All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines * Tissue blocks or slides must be sent for all patients; if tissue blocks or slides are unavailable, the study chair must be notified prior to enrollment
Exclusion criteria
* Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as there is yet no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in girls who are post-menarchal; women of childbearing potential (WOCBP) receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of nivolumab; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of nivolumab * Patients requiring daily systemic corticosteroids are not eligible; patients must not have received systemic corticosteroids within 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid; Note: use of topical or inhaled corticosteroids will not render a patient ineligible * Patients who are currently receiving another investigational drug are not eligible * Patients who are currently receiving other anti-cancer agents are not eligible * Patients with CNS tumors or known CNS metastases will be excluded from this trial; patients with a history of CNS metastases that have been previously treated may enroll if sequential imaging shows not evidence for active disease; patients with extra axial disease (e.g. skull \[bone\] metastasis that do not invade the dura) may enroll if there is no evidence for CNS edema associated with the lesion * Patients with a history of any grade autoimmune disorder are not eligible; asymptomatic laboratory abnormalities (e.g. antinuclear antibody \[ANA\], rheumatoid factor, altered thyroid function studies) will not render a patient ineligible in the absence of a diagnosis of an autoimmune disorder * Patients with \>= grade 2 hypothyroidism due to history of autoimmunity are not eligible; note: hypothyroidism due to previous irradiation on thyroidectomy will not impact eligibility * Patients who have an uncontrolled infection are not eligible * Patients with a history of congestive heart failure (CHF) or are at risk because of underlying cardiovascular disease or exposure to cardiotoxic drugs must have adequate cardiac function as clinically indicated: * Corrected QT interval (QTC) =\< 480 msec * Shortening fraction of \>= 27% by echocardiogram or ejection fraction of \>= 50% by gated radionuclide study * Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excluded * Patients who have received prior solid organ transplantation are not eligible * Patient who have received allotransplantation are not eligible * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible * Patients who have received prior anti-PD1 directed therapy (monoclonal antibody \[mAb\] or small molecule) are not eligible * Parts C, D, and E: patients who have received prior ipilimumab are not eligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 28 days | The frequency (%) of patients experiencing a dose limiting toxicity at least possibly attributable to nivolumab as a single agent or in combination with ipilimumab by study part and dose level. |
| Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 5 years | Frequency of disease response (best overall response of partial or complete response) assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR by study part and dose level. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Half-life of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 15 days | The median (min,max) of the half-life of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose. The reported half-life was calculated using a linear regression of the log (concentration) versus time data for days 4, 8 and 15. |
| Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 15 days | Median (min,max) of the maximum serum concentration of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose. |
| Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 15 days | Median (min,max) of the minimum serum concentration of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose. |
| Pharmacodynamics of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 28 days | Median (min,max) concentration by protein, study part, and dose level. |
| PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | Cycle 1 (21 days) | Median (min, max) of PD-L1 expression levels by study part, dose level, and disease cohort. |
| Biomarker Expression Analysis of Nivolumab as a Single Agent or in Combination With Ipilimumab | Cycle 1 (21 days) | Median (min, max) expression levels by biomarker, dose level, study part, and disease cohort. |
| Clearance of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 15 days | Median (min,max) of the clearance of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose. |
| Area Under the Drug Concentration Curve of Nivolumab as a Single Agent or in Combination With Ipilimumab | Up to 15 days | The median (min,max) of the area under the drug concentration curve for nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24,72,192, and 360 hours post-dose. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Part A: 3 mg/kg Nivolumab Phase 1: Patients with solid tumors, excluding brain and CNS tumors | 7 |
| Part A PK: 3 mg/kg Nivolumab Phase 1: Patients with solid tumors, excluding brain and CNS tumors receive | 6 |
| Part B: 3 mg/kg Nivolumab Patients with relapsed or refractory neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing Sarcoma or Peripheral PNET, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, unresectable melanoma or metastatic melanoma or relapsed melanoma or refractory melanoma, neuroblastoma (MIBG evaluable without RECIST evaluable disease) | 72 |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab Phase 1: patients with solid tumors, excluding brain and CNS tumors | 6 |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab Phase 1: patients with solid tumors, excluding brain and CNS tumors | 6 |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab Phase 1: patients with solid tumors, excluding brain and CNS tumors | 6 |
| Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab Patients with relapsed or refractory osteosarcoma, rhabdomyosarcoma, Ewing Sarcoma or Peripheral PNET | 29 |
| Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab Patients with relapsed or refractory rhabdomyosarcoma, Ewing Sarcoma, or Peripheral PNET | 8 |
| Total | 140 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 7 | 0 | 0 | 0 | 3 | 4 |
| Overall Study | Death | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Lack of Efficacy | 4 | 6 | 38 | 5 | 6 | 6 | 21 | 4 |
| Overall Study | Physician Decision | 2 | 0 | 16 | 1 | 0 | 0 | 3 | 0 |
| Overall Study | Protocol Violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 7 | 0 | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Part A PK: 3 mg/kg Nivolumab | Part B: 3 mg/kg Nivolumab | Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Part A: 3 mg/kg Nivolumab | Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 6 Participants | 59 Participants | 6 Participants | 6 Participants | 6 Participants | 18 Participants | 7 Participants | 4 Participants | 112 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 13 Participants | 0 Participants | 0 Participants | 0 Participants | 11 Participants | 0 Participants | 4 Participants | 28 Participants |
| Age, Continuous | 9.5 years | 15 years | 15 years | 14.5 years | 8.5 years | 17 years | 12 years | 19 years | 15 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 9 Participants | 1 Participants | 1 Participants | 1 Participants | 5 Participants | 2 Participants | 1 Participants | 21 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 62 Participants | 5 Participants | 5 Participants | 5 Participants | 23 Participants | 5 Participants | 7 Participants | 117 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 5 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 8 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 12 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 6 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants | 0 Participants | 0 Participants | 12 Participants |
| Race (NIH/OMB) White | 6 Participants | 51 Participants | 3 Participants | 4 Participants | 4 Participants | 23 Participants | 7 Participants | 8 Participants | 106 Participants |
| Sex: Female, Male Female | 1 Participants | 28 Participants | 1 Participants | 3 Participants | 4 Participants | 8 Participants | 5 Participants | 5 Participants | 55 Participants |
| Sex: Female, Male Male | 5 Participants | 44 Participants | 5 Participants | 3 Participants | 2 Participants | 21 Participants | 2 Participants | 3 Participants | 85 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 7 | 3 / 6 | 38 / 72 | 2 / 6 | 4 / 6 | 4 / 6 | 19 / 29 | 1 / 8 |
| other Total, other adverse events | 7 / 7 | 6 / 6 | 72 / 72 | 6 / 6 | 6 / 6 | 6 / 6 | 29 / 29 | 8 / 8 |
| serious Total, serious adverse events | 6 / 7 | 6 / 6 | 70 / 72 | 4 / 6 | 6 / 6 | 5 / 6 | 26 / 29 | 7 / 8 |
Outcome results
Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab
Frequency of disease response (best overall response of partial or complete response) assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR by study part and dose level.
Time frame: Up to 5 years
Population: All Eligible patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part A PK: 3 mg/kg Nivolumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part B: 3 mg/kg Nivolumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 3 Participants |
| Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 1 Participants |
| Part B7: 3 mg/kg Nivolumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part B8: 3 mg/kg Nivolumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part D2: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part D3: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 1 Participants |
| Part D4: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 1 Participants |
| Part E3: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part E4: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab
The frequency (%) of patients experiencing a dose limiting toxicity at least possibly attributable to nivolumab as a single agent or in combination with ipilimumab by study part and dose level.
Time frame: 28 days
Population: All Eligible patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part A PK: 3 mg/kg Nivolumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part B: 3 mg/kg Nivolumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 5 Participants |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 Participants |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 1 Participants |
| Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 1 Participants |
| Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab | 1 Participants |
Area Under the Drug Concentration Curve of Nivolumab as a Single Agent or in Combination With Ipilimumab
The median (min,max) of the area under the drug concentration curve for nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24,72,192, and 360 hours post-dose.
Time frame: Up to 15 days
Population: All eligible patients with data collected. Data not collected for Parts C, D, and E
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Area Under the Drug Concentration Curve of Nivolumab as a Single Agent or in Combination With Ipilimumab | 20744.5 hr*ug/mL |
| Part A PK: 3 mg/kg Nivolumab | Area Under the Drug Concentration Curve of Nivolumab as a Single Agent or in Combination With Ipilimumab | 18338 hr*ug/mL |
| Part B: 3 mg/kg Nivolumab | Area Under the Drug Concentration Curve of Nivolumab as a Single Agent or in Combination With Ipilimumab | 20816 hr*ug/mL |
Biomarker Expression Analysis of Nivolumab as a Single Agent or in Combination With Ipilimumab
Median (min, max) expression levels by biomarker, dose level, study part, and disease cohort.
Time frame: Cycle 1 (21 days)
Population: Data were not and will never be collected
Clearance of Nivolumab as a Single Agent or in Combination With Ipilimumab
Median (min,max) of the clearance of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose.
Time frame: Up to 15 days
Population: All eligible patients with data collected. Data not collected for Parts C, D, and E
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Clearance of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0.1 mL/hr/kg |
| Part A PK: 3 mg/kg Nivolumab | Clearance of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0.2 mL/hr/kg |
| Part B: 3 mg/kg Nivolumab | Clearance of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0.1 mL/hr/kg |
Half-life of Nivolumab as a Single Agent or in Combination With Ipilimumab
The median (min,max) of the half-life of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose. The reported half-life was calculated using a linear regression of the log (concentration) versus time data for days 4, 8 and 15.
Time frame: Up to 15 days
Population: All eligible patients with data collected. Data not collected for Parts C, D, and E
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Half-life of Nivolumab as a Single Agent or in Combination With Ipilimumab | 312.5 hours |
| Part A PK: 3 mg/kg Nivolumab | Half-life of Nivolumab as a Single Agent or in Combination With Ipilimumab | 281.5 hours |
| Part B: 3 mg/kg Nivolumab | Half-life of Nivolumab as a Single Agent or in Combination With Ipilimumab | 379 hours |
Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab
Median (min,max) of the maximum serum concentration of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose.
Time frame: Up to 15 days
Population: All eligible patients with data collected
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 80.9 ug/mL |
| Part A PK: 3 mg/kg Nivolumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 72 ug/mL |
| Part B: 3 mg/kg Nivolumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 68.1 ug/mL |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 17.3 ug/mL |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 43.3 ug/mL |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 41.7 ug/mL |
| Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 34.6 ug/mL |
| Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Maximum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 49.1 ug/mL |
Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab
Median (min,max) of the minimum serum concentration of nivolumab as a single agent or in combination with ipilimumab by study part and dose level. Measured during cycle 1 at 0, 24, 72, 192, and 360 hours post-dose.
Time frame: Up to 15 days
Population: All eligible patients with data collected
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 29.6 ug/mL |
| Part A PK: 3 mg/kg Nivolumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 30.4 ug/mL |
| Part B: 3 mg/kg Nivolumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 26.4 ug/mL |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 3.8 ug/mL |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 10.5 ug/mL |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 9.2 ug/mL |
| Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 10.8 ug/mL |
| Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | Minimum Serum Concentration of Nivolumab as a Single Agent or in Combination With Ipilimumab | 8 ug/mL |
PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab
Median (min, max) of PD-L1 expression levels by study part, dose level, and disease cohort.
Time frame: Cycle 1 (21 days)
Population: All Eligible patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: 3 mg/kg Nivolumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part A PK: 3 mg/kg Nivolumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part B: 3 mg/kg Nivolumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 2.5 percent |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part D: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 100 percent |
| Part E: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 7.5 percent |
| Part B7: 3 mg/kg Nivolumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part B8: 3 mg/kg Nivolumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part C: 1mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part C: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 3 percent |
| Part C PK: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part D2: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part D3: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part D4: 3mg/kg Nivolumab and 1mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part E3: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
| Part E4: 1mg/kg Nivolumab and 3mg/kg Ipilimumab | PD-L1 Expression of Nivolumab as a Single Agent or in Combination With Ipilimumab | 0 percent |
Pharmacodynamics of Nivolumab as a Single Agent or in Combination With Ipilimumab
Median (min,max) concentration by protein, study part, and dose level.
Time frame: Up to 28 days
Population: Data were not and will never be collected